HEALEY ALS Platform Trial: Mechanism of Action and Science Webinar - DNL343, Regimen G

Explore the science behind DNL343, the investigational product being tested in Regimen G of the HEALEY ALS Platform Trial, in this informative 48-minute webinar. Join Merit Cudkowicz, MD, MSc and regimen co-lead Suma Babu, MBBS, MPH, from Massachusetts General Hospital, along with research scientists from Denali Therapeutics, as they present the rationale and scientific basis for this potential ALS treatment. Learn about the mechanism of action of DNL343 and gain insights into its role in the HEALEY ALS Platform Trial. Engage with the experts during the Q&A session to deepen your understanding of this promising research. For those interested in staying informed about ALS research and future webinars, visit the Mass General website to register for upcoming events and sign up for the ALS Link newsletter. Connect with MGH Neurology on Facebook and Twitter for additional updates and information.

HEALEY ALS Platform Trial: Mechanism of Action & Science Webinar: DNL343, Regimen G